# Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

> **NCT00134004** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 210 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate
- **DRUG:** mycophenolate mofetil
- **DRUG:** tacrolimus
- **PROCEDURE:** allogeneic bone marrow transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00134004
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-10
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2015-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00134004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00134004, "Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00134004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*